• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Comments on "Radiotherapy alone versus concurrent chemoradiotherapy in patients with stage II and T3N0 nasopharyngeal carcinoma with adverse features: A propensity score-matched cohort study".

作者信息

Beduk Esen Caglayan Selenge, Can Gizem Nur, Akkus Yildirim Berna

机构信息

Department of Radiation Oncology, Prof. Dr. Cemil Taşcıoğlu City Hospital, Istanbul, Turkey.

Department of Radiation Oncology, Prof. Dr. Cemil Taşcıoğlu City Hospital, Istanbul, Turkey.

出版信息

Radiother Oncol. 2024 Aug;197:110292. doi: 10.1016/j.radonc.2024.110292. Epub 2024 Apr 20.

DOI:10.1016/j.radonc.2024.110292
PMID:38648993
Abstract
摘要

相似文献

1
Comments on "Radiotherapy alone versus concurrent chemoradiotherapy in patients with stage II and T3N0 nasopharyngeal carcinoma with adverse features: A propensity score-matched cohort study".对“II期和T3N0有不良特征的鼻咽癌患者单纯放疗与同步放化疗的比较：一项倾向评分匹配队列研究”的评论
Radiother Oncol. 2024 Aug;197:110292. doi: 10.1016/j.radonc.2024.110292. Epub 2024 Apr 20.
2
Response to "Comments on 'Radiotherapy alone versus concurrent chemoradiotherapy in patients with stage II and T3N0 nasopharyngeal carcinoma with adverse features: A propensity score-matched cohort study'".对《II期和T3N0伴不良特征鼻咽癌患者单纯放疗与同步放化疗的比较：一项倾向评分匹配队列研究》评论的回应
Radiother Oncol. 2024 Aug;197:110327. doi: 10.1016/j.radonc.2024.110327. Epub 2024 May 11.
3
Radiotherapy alone versus concurrent chemoradiotherapy in patients with stage II and T3N0 nasopharyngeal carcinoma with adverse features: A propensity score-matched cohort study.单纯放疗与同期放化疗治疗伴有不良特征的 II 期和 T3N0 鼻咽癌患者的比较：一项倾向评分匹配队列研究。
Radiother Oncol. 2024 May;194:110189. doi: 10.1016/j.radonc.2024.110189. Epub 2024 Mar 1.
4
Survival of stage II nasopharyngeal carcinoma patients with or without concurrent chemotherapy: A propensity score matching study.无同步放化疗的 II 期鼻咽癌患者与有同步放化疗的 II 期鼻咽癌患者的生存比较：一项倾向评分匹配研究。
Cancer Med. 2020 Feb;9(4):1287-1297. doi: 10.1002/cam4.2785. Epub 2019 Dec 20.
5
Can neoadjuvant chemotherapy improve survival in stage T3-4N1 nasopharyngeal carcinoma? A propensity matched analysis.新辅助化疗能否提高 T3-4N1 期鼻咽癌患者的生存率？一项倾向评分匹配分析。
Radiat Oncol. 2020 Jul 2;15(1):160. doi: 10.1186/s13014-020-01594-4.
6
Effect of Radiotherapy Alone vs Radiotherapy With Concurrent Chemoradiotherapy on Survival Without Disease Relapse in Patients With Low-risk Nasopharyngeal Carcinoma: A Randomized Clinical Trial.单纯放疗与同期放化疗对低危鼻咽癌患者无疾病复发生存的影响：一项随机临床试验。
JAMA. 2022 Aug 23;328(8):728-736. doi: 10.1001/jama.2022.13997.
7
The Role of Neoadjuvant Chemotherapy in the Treatment of Nasopharyngeal Carcinoma: A Multi-institutional Retrospective Study (KROG 11-06) Using Propensity Score Matching Analysis.新辅助化疗在鼻咽癌治疗中的作用：一项使用倾向评分匹配分析的多机构回顾性研究（KROG 11-06）
Cancer Res Treat. 2016 Jul;48(3):917-27. doi: 10.4143/crt.2015.265. Epub 2015 Dec 28.
8
T4/N2 classification nasopharyngeal carcinoma benefit from concurrent chemotherapy in the era of intensity-modulated radiotherapy.T4/N2 分期鼻咽癌在调强放疗时代可从同步化疗中获益。
Oncotarget. 2016 Dec 6;7(49):81918-81925. doi: 10.18632/oncotarget.11981.
9
Neoadjuvant chemotherapy combined with concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone on locally advanced nasopharyngeal carcinoma.
J Biol Regul Homeost Agents. 2020 Nov-Dec;34(6):2115-2119. doi: 10.23812/20-290-L.
10
Radiotherapy Alone vs Radiotherapy With Concurrent Chemoradiotherapy and Survival of Patients With Low-Risk Nasopharyngeal Carcinoma.单纯放疗与同步放化疗治疗低危鼻咽癌患者的疗效及生存情况比较
JAMA. 2023 Jan 17;329(3):261. doi: 10.1001/jama.2022.21033.